Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 10/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.34 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.34 |
| ▸ | CCKAR | P32238 | 2/20 | 0.34 |
| ▸ | CCKBR | P32239 | 2/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | F12 | P00748 | 1/20 | 0.33 |
| ▸ | CASR | P41180 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6134738 | 0.91 | ADORA3 (0.39) | TP53 | |
| SCHEMBL6134384 | 0.90 | KMT2A (0.40) | TP53 | |
| SCHEMBL6133995 | 0.89 | TP53 (0.38) | TP53NTRK1GRM5F2 | |
| SCHEMBL6134200 | 0.89 | POLB (0.39) | TP53F2 | |
| SCHEMBL6135302 | 0.87 | ALDH1A1 (0.37) | TP53CCKARF2 | |
| SCHEMBL6133600 | 0.85 | GRM5 (0.43) | TP53NTRK1GRM5NTRK3 | |
| SCHEMBL6133753 | 0.84 | TP53 (0.38) | TP53 | |
| SCHEMBL6133485 | 0.79 | ALDH1A1 (0.44) | TP53 | |
| SCHEMBL6133461 | 0.77 | ADORA1 (0.43) | — | |
| SCHEMBL6134310 | 0.76 | GAA (0.45) | TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ASTELLAS PHARMA INC. (JP) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043315-A1 | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them | ADORA2B, ADORA2A, ADORA1 | TP53 2834/4885NTRK1 4294/4885GRM5 270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.